Related Experiment Video
Updated: Nov 28, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint
Roberta Noseda1, Lorenzo Ruinelli2, Linda C van der Gaag3
1Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Pre-existing cardiovascular conditions may increase the risk of immune checkpoint inhibitor (ICI)-related myocarditis. This study suggests a link between cardiovascular treatments and ICI-related myocarditis reporting, highlighting the need for further research.
Area of Science:
- Pharmacovigilance
- Cardiology
- Oncology
Background:
- Immune checkpoint inhibitors (ICIs) are increasingly prescribed for cancer treatment.
- ICI-related myocarditis is a rare but potentially fatal adverse drug reaction (ADR).
- Identifying risk factors for ICI-related myocarditis is crucial due to rising ICI usage.
Purpose of the Study:
- To investigate the association between pre-existing cardiovascular (CV) conditions and the reporting of ICI-related myocarditis.
- To analyze data from VigiBase, the WHO global database of suspected ADRs.
Main Methods:
- A retrospective matched case-control study was conducted.
- 108 cases of ICI-related myocarditis were compared with 108 controls of other ICI-related ADRs.
- Drugs for CV conditions served as a proxy for pre-existing CV risk factors or diseases.
Main Results:
- Drugs used for cardiovascular conditions were significantly associated with ICI-related myocarditis reporting (p=0.026).
- No significant association was found between pre-existing diabetes and ICI-related myocarditis reporting (p=0.752).
Conclusions:
- Pre-existing cardiovascular conditions may be associated with an increased risk of ICI-related myocarditis.
- Further prospective studies are needed to establish a causal relationship.
- These findings emphasize the importance of monitoring cardiovascular health in patients receiving ICI therapy.
More Related Videos
12:24Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations
Myocarditis IV: Nursing Management